What Grifols is and where it is based
Grifols, S.A. is the Spanish parent of a group focused mainly on plasma-derived medicines and diagnostic solutions. Its tax ID is A58389123, and its registered and tax address is Avinguda de la Generalitat, 152–158, Sant Cugat del Vallès, Barcelona. The current company was incorporated on 22 June 1987; that legal date differs from the historical origins of the business. This profile uses the worldwide consolidated scope of Grifols and its subsidiaries. Sources: 2025 accounts: identity, registered office and facilities; Legal notice: tax ID and commercial registration.
Industrial companies, donation centres and commercial subsidiaries perform different functions. The parent provides administration, management and control services and invests in its subsidiaries. Group sales and employment should therefore not be attributed solely to the parent company or to a Spanish factory. Sources: 2025 accounts: identity, registered office and facilities.
From a family laboratory to international expansion
Grifols traces its origins to the clinical analysis laboratory established in Barcelona in 1909 by Josep Antoni Grifols i Roig. In 1940, he and his sons Josep Antoni and Víctor founded Laboratorios Grifols. Techniques and instruments for collecting, preserving and processing blood shaped the company’s development. In 1987, a holding structure brought together its production and commercial businesses. Sources: History: from the 1909 laboratory to an international group.
Listing on Spain’s continuous market in 2006 and the acquisitions of Talecris Biotherapeutics in 2011 and Biotest in 2022 expanded the group’s scale. In June 2025, Grifols completed Biotest’s delisting after increasing its stake to 80.4% of share capital and 99.25% of voting rights. Biotest is a subsidiary integrated into Grifols, rather than another group to add again to its consolidated figures. Sources: History: from the 1909 laboratory to an international group; Biotest, Canada and Egypt project in 2025.
Ownership: distinguishing capital from voting rights
At year-end 2025, the accounts identified Deria, S.L. with 15.20% of voting rights, Scranton Enterprises, B.V. with 8.40% and Ponder Trade, S.L. with 7.09%. These are published voting percentages for that date, rather than a real-time snapshot or percentages interchangeable with economic ownership. The structure includes Class A shares and non-voting Class B shares. Sources: Voting rights at year-end 2025; 2025 accounts: identity, registered office and facilities.
Family origins remain relevant to understanding Grifols’ development, but ownership, board representation and executive management should be separated. The name of a foreign shareholder company does not automatically make the Spanish group a subsidiary controlled by a foreign parent. This profile does not combine stakes as though there were a single shareholder without documenting that relationship. Sources: Voting rights at year-end 2025; Current board of directors.
Current leadership in November 2026
On 8 November 2026, Anne-Catherine Berner is the independent non-executive chair, and Nacho Abia is chief executive officer. Raimon Grifols Roura is listed as vice-chair and a proprietary director. Víctor Grifols Roura appears as honorary chair without board membership; he should not be confused with Víctor Grifols Deu, who is listed as a proprietary director. Sources: Current board of directors; Anne-Catherine Berner: non-executive chair.
The executive committee separates responsibilities for plasma procurement, industrial services, diagnostics, finance and people. Separating the board chair from executive management identifies who oversees corporate governance and who leads operations, without carrying former joint executive roles into the present. Sources: Executive committee and responsibilities; Current board of directors.
How the business works
Plasma procurement, fractionation and purification, manufacturing and medicine commercialisation form the core of Biopharma. Areas of activity include immunology and neurology, haematology, pulmonary disease and intensive care. Diagnostic develops blood and plasma testing solutions; Bio Supplies provides biological materials for non-therapeutic uses such as research and diagnostics. Sources: Business model and therapeutic areas; Value chain: donation, manufacturing and distribution.
In 2025, Biopharma contributed EUR6,487 million in revenue; Diagnostic EUR640 million; Bio Supplies EUR154 million; and other businesses EUR243 million. Biopharma’s weight explains the importance of maintaining plasma supply and industrial capacity. Donor safety, medicine quality and occupational safety require their own controls: a product’s regulatory approval does not, by itself, demonstrate a plant’s OHS performance. Sources: 2025 revenue by business and region; Business model and therapeutic areas; Assessment, training, ISO 45001 and contractors.
Products, brands and diagnostic solutions
The 2025 report identifies specific products within these activities. Grifols and Biotest launched Yimmugo in the United States: an intravenous immunoglobulin manufactured in Germany, with US distribution managed by Kedrion. Personalised kits for home administration of Xembify, a subcutaneous immunoglobulin, were launched in Spain. Commercialisation of the fibrinogen concentrate Prufibry also began in Germany. These milestones concern particular markets and dates; they do not imply universal availability of each product.
Products, brands and diagnostic solutions · p. 219
In diagnostics, DG Gel cards are used for blood typing, and production began at the new San Diego plant in 2025. The same report records an FDA application for Procleix UltrioPlex W, a donor-screening assay combining detection of several pathogens. The application is described as a 2025 regulatory step, without presenting it as an authorisation already obtained.
Industrial footprint and geographical scope
The 2025 accounts identify major facilities in Parets del Vallès and Murcia; Los Angeles, Clayton, Emeryville and San Diego in the United States; and Dublin, Montreal and Dreieich. US and Canadian revenue totalled EUR4,253 million, European Union revenue EUR1,614 million and the rest of the world EUR1,657 million. These are commercial revenue areas, rather than a distribution of employee or factory numbers. Sources: 2025 accounts: identity, registered office and facilities; 2025 revenue by business and region.
Progenika Biopharma, included in the group’s subsidiary schedule, develops, produces and markets biotechnology solutions in Bizkaia. This profile’s photograph shows its technology-park premises in 2018. It illustrates a group subsidiary, rather than the registered office in Sant Cugat or current safety conditions inside the facility. Sources: Subsidiary schedule: Progenika Biopharma.
2025 figures and comparison method
The latest complete annual financial year available ended on 31 December 2025. The consolidated accounts under EU-adopted IFRS report net revenue of EUR7,524 million, compared with EUR7,212 million in 2024. Operating profit was EUR1,243 million and profit attributable to the parent EUR402 million. Total consolidated net profit, including non-controlling interests, was EUR500 million. Sources: Official annual accounts archive; 2025 consolidated IFRS income statement.
Reported revenue growth was 4.3%; the published 7.0% constant-currency increase removes exchange-rate effects and uses an adjusted measure. The two rates are not calculated on the same basis. Similarly, EUR7,759 million of net financial debt under the credit agreement and its 4.2-times leverage ratio use their own reconciliations. They do not replace revenue, profit or cash generation. Sources: Constant-currency revenue reconciliation; Debt and EBITDA under the credit agreement.
Workforce and scope of social data
The 2025 integrated report records 25,247 people with active employment contracts at year-end: 14,310 in the United States, 4,665 in Spain, 3,957 in Germany and 2,315 elsewhere. Permanent contracts accounted for 98%. This definition excludes board members except the CEO and differs from the financial-account tables and average workforce calculated using another method. Sources: Year-end 2025 workforce and definition.
In 2025, Biotest data were harmonised for inclusion in sustainability reporting, having previously been presented partly in separate tables. Social comparisons therefore require attention to scope notes. The four countries highlighted in accident indicators—the United States, Spain, Ireland and Germany—represent approximately 94% of the workforce, while management-system coverage is reported for 100% of employees. Sources: Sustainability scope and Biotest integration; 2025 LTIFR: methodology change and coverage.
OHS organisation and site certification
Grifols describes a corporate health and safety policy, a cross-functional corporate department and local systems adapted to subsidiaries. Self-assessments and targeted audits operate over three-year cycles. The report documents accident and incident reporting in Spain and near-miss reporting in the United States, alongside investigation and follow-up of corrective action. Sources: OHS governance and incident reporting.
For 2025, the company identifies ISO 45001 certification at its Spanish industrial complexes and Emeryville, and reports that San Diego obtained certification during the year. Reaching 75% of global manufacturing facilities by 2030 is a future target. Declared management-system coverage of the entire workforce does not mean group-wide certification; this profile records the reported scope without verifying each individual certificate’s validity in 2026. Sources: Assessment, training, ISO 45001 and contractors; 2025 LTIFR: methodology change and coverage.
Assessment, facility design and training
The corporate standard requires workplace risk assessments and action plans with measurable objectives and priorities. Prevention is incorporated into facility design, process adaptation and equipment procurement. Monitoring combines inspections, safe-behaviour observations, audits and incident and near-miss reports. The report recognises that manufacturing facilities and donation centres have different risk profiles. Sources: Assessment, training, ISO 45001 and contractors.
Training combines general and role-specific content with first aid, cardiopulmonary resuscitation, defibrillators and modules such as OSHA ten-hour training. In 2025, the company reported 60,730 hours of health, safety and environmental training, reaching 73% of employees in these subjects. The total includes environmental content: it is not entirely occupational prevention training and does not, by itself, establish that an exposure was eliminated. Sources: Assessment, training, ISO 45001 and contractors; Health, safety and environmental training.
Coordination with contractors
In manufacturing, digital platforms require contractors to maintain current prevention plans before entering facilities and working. Spain and Ireland use document systems to check requirements before tasks begin. North American operations use ISNetworld to assess and qualify contractors for safety and compliance. Some locations add external providers that assess contractors’ safety metrics for the preceding three years. Sources: Assessment, training, ISO 45001 and contractors.
The 2025 documentation contains a discrepancy that limits interpretation of outcomes: the general narrative reports a zero contractor LTIFR, while the Ireland table records one lost-time accident and a frequency index of 15. This profile therefore does not publish a conclusion of zero contractor accidents across the group. The table also identifies several earlier-year comparative contractor figures as unavailable. Sources: 2025 LTIFR: methodology change and coverage; Ireland and Germany accidents, including contractors; US and Spain accidents: tables and methodology.
Accidents: methodology change and valid comparisons
LTIFR counts lost-time injuries per million hours worked. In 2025, Grifols harmonised US and European criteria and moved restricted-work cases into the non-lost-time category. The 2025 value is 2.79 under the revised method, compared with 3.75 under the previous method. The 4.52 published for 2024 should not be compared with 2.79 as though the entire difference resulted from improved prevention. Sources: 2025 LTIFR: methodology change and coverage.
The national tables exclude commuting accidents from lost-time counts. Spain recorded a combined 24 lost-time accidents in 2025—8 involving women and 16 men—compared with 69 in 2024. US totals were 62 versus 77. Tables for the four countries show zero deaths from work-related injuries or ill health in 2025; the US table does record two cases of recordable occupational ill health. Retaining each population and definition avoids confusing no deaths with no illness or accidents. Sources: US and Spain accidents: tables and methodology; Ireland and Germany accidents, including contractors.
Mental health and local initiatives
The mental health policy has been in place since 2023 and is organised around prevention, detection and action. The report describes awareness and training, questionnaires and risk assessments, communication channels, psychological consultations and plans arising from detection tools. The Total Health Plan launched in 2025; a new plan envisaged for 2026 appears as future development in that report and is not presented here as verified implementation. Sources: Mental health and local wellbeing initiatives.
Local initiatives include ergonomic visits, physiotherapy and role-specific medical examinations in Spain, and vaccination campaigns and wellbeing activities in North America. The 65% positive emotional-health figure comes from respondents to an indicator introduced in the 2024 survey. It is neither a clinical measurement of the entire workforce nor a causal outcome attributed to 2025 actions. Sources: Mental health and local wellbeing initiatives.
Documented innovation and artificial intelligence
The 2025 income statement records EUR426 million in research and development expense. The report describes generative AI used in preparing scientific and regulatory documentation, proteomic analysis with Alkahest to identify early Parkinson’s biomarkers, and GigaGen machine learning to design polyclonal antibodies. These are reported uses in research and business processes, rather than clinical or OHS outcomes demonstrated by this profile. Sources: 2025 consolidated IFRS income statement; Digital innovation and artificial intelligence initiatives.
It also documents OneKey integration into Biopharma’s German CRM to improve information on healthcare professionals and organisations; Spain is identified as the next planned implementation. Digital tools for documentation or research do not establish the existence of an AI system to monitor workers or prevent accidents, functions not substantiated by these sources. Sources: Digital innovation and artificial intelligence initiatives.
Materials, waste and their relevance to prevention
Plasma fractionation uses adjustments to temperature, pH and ethanol concentration to separate proteins. The report also identifies polyethylene glycol and sorbitol among the materials used. This process description helps explain why assessment must be tailored to substances, equipment and tasks; it does not replace a specific exposure assessment for each job. Sources: Raw materials and fractionation process; Assessment, training, ISO 45001 and contractors.
In 2025, reported waste generation totalled 78,071 tonnes, of which 21,203 were classified as hazardous. These are environmental quantities for the reported scope, rather than measures of occupational accidents or health effects. Waste classification and management matter to operations, but they do not, by themselves, establish how each risk to workers handling that waste was controlled. Sources: Generated waste and hazardous classification.
Financial transparency and appeal status
Spain’s official gazette on 6 August 2025 published sanctions against Grifols, S.A. of EUR800,000 for regulated financial information for 2021–2023 and the first half of 2023 containing inaccurate or untruthful data or material omissions, and EUR200,000 for misleading information about the calculation of alternative performance measures. The decision concerns financial disclosure; it is not an occupational-safety sanction. Sources: Official gazette: sanctions published on 6 August 2025.
On 19 January 2026, the CNMV recorded that Grifols and the sanctioned current and former directors had filed a judicial administrative appeal, pending at that date. The sanctions were final in the administrative process and subject to judicial review. This profile retains both facts without claiming to have verified a subsequent judgment. The distinction reinforces the need to identify sources and reconciliations when comparing group figures. Sources: CNMV: judicial appeal pending on 19 January 2026; Official gazette: sanctions published on 6 August 2025.
What the 2026 information changes
The 2 November 2026 release reports EUR5,614 million of revenue for the first nine months and EUR390 million of cumulative net profit, as presented by the company. These are interim figures; they do not replace the 2025 annual financial year used for editorial selection in this profile. Management roles have instead been checked against current corporate pages at the review date. Sources: Third-quarter 2026 results; Current board of directors.
The useful OHS lesson combines a complex industrial chain with specific controls: safe design, job-level assessment, incident reporting, contractor qualification and indicators interpreted with their methodology. Business expansion and innovation provide context; OHS evidence lies in these activities and their documented outcomes. The reviewed sources do not establish a commercial relationship with Sabentis. Sources: Value chain: donation, manufacturing and distribution; Assessment, training, ISO 45001 and contractors; 2025 LTIFR: methodology change and coverage; US and Spain accidents: tables and methodology; Ireland and Germany accidents, including contractors.
Frequently asked questions
Where is Grifols based?
Grifols, S.A.’s registered and tax address is Avinguda de la Generalitat, 152–158, Sant Cugat del Vallès, Barcelona. Factories and subsidiaries have other addresses; the photograph shows Progenika in Bizkaia. [1] · [2] · [3]
How much revenue did Grifols earn in 2025?
The consolidated group reported EUR7,524 million in net revenue under IFRS. Profit attributable to the parent was EUR402 million; the two are different measures. [1]
Who leads Grifols?
On 8 November 2026, Anne-Catherine Berner is non-executive chair and Nacho Abia is CEO. Víctor Grifols Roura is listed as honorary chair without board membership. [1]
Is all of Grifols ISO 45001 certified?
The 2025 report identifies certified facilities in Spain, Emeryville and San Diego. Reaching 75% of manufacturing facilities by 2030 is a target, not evidence of group-wide certification. [1]
Why are there two LTIFR figures for 2025?
Grifols reclassified restricted-work cases to harmonise US and European reporting. The 2025 result is 2.79 under the revised method and 3.75 under the previous method, per million hours. Historical comparisons must retain the methodology. [1]
What contractor controls does it use?
It documents prevention plans before access, document checks in Spain and Ireland, ISNetworld in North America and corporate audits. The discrepancy between the general narrative and the Ireland table prevents a claim of zero contractor accidents across the group. [1] · [2] · [3]
